Ranexa May Launch In 2006; CV Therapeutics And FDA Discussing New Study
This article was originally published in The Pink Sheet Daily
Executive Summary
The company expects to obtain a special protocol assessment for the trial, which will likely focus on a restricted angina population. After approval, CVT expects to expand the label through additional studies.
You may also be interested in...
CV Therapeutics Ranexa Benefit Over Norvasc Will Be Focus Of Additional Phase III Trial
Refractory angina trial designed under a special protocol assessment with FDA will begin in the third quarter. The company predicts a "broad restricted label" based on the study, which follows recommendations made by FDA's Cardio-Renal Drugs Advisory Committee.
Barr’s Expanded Thalidomide ANDA Could Increase Likelihood Of A Marketed Generic
Amended application includes 50 mg and 100 mg dosage forms, which are used in multiple myeloma.